MS-N188 · Culturally rooted mind–body movement · Appraised October 30, 2026

Tibetan yoga for sleep during breast-cancer chemotherapy

Aliases: Tibetan yoga program

Evidence at a glance

Question: Does a Tibetan yoga program improve sleep disturbance or fatigue during breast-cancer chemotherapy?
Finding: A three-arm randomized trial found no overall group difference in total sleep disturbance or fatigue. Modest short-term sleep-component signals and practice-associated findings were exploratory and should not override the negative primary results.
Evidence label: Primary outcomes negative; limited secondary signals
Benefit: No established overall sleep or fatigue benefit.
Certainty: Moderate for the null primary outcomes; low for adherence-based and component-level signals.
Risk: No intervention-related adverse events were reported, but mobility and treatment-related limitations require adaptation.
Cancer-control boundary: The program was tested for supportive symptoms, not tumor response, recurrence or survival.

Study details

Intervention: Four 75–90-minute Tibetan yoga sessions during chemotherapy, printed and recorded home materials, encouragement for daily practice and three later booster sessions.
Comparator: Stretching program with similar instructional exposure and usual-care waitlist.
Population: Women with stage I–III breast cancer receiving neoadjuvant or adjuvant chemotherapy.
Design and sample: Three-arm randomized trial. 352 completed baseline and were randomized; the evaluable analysis included 227: 74 yoga, 68 stretching and 85 usual care.
Primary outcomes: Total sleep disturbance and fatigue, assessed after treatment and through 12 months; actigraphy supplemented self-report.
Results: No significant group-by-time effect for total sleep disturbance (P=.96) and no overall fatigue difference. Yoga showed fewer daily disturbances at one week versus both comparators; adherent participants had better later sleep outcomes in nonrandomized practice analyses.
Negative findings: Primary total-sleep and fatigue outcomes were null. Actigraphy data were missing for 31% of questionnaire completers.
Limitations: Large loss before evaluable analysis, low booster attendance, adherence analyses susceptible to healthy-participant bias, and a specialized tradition/instructor setting.
Funding and conflicts: Supported by US NCCIH and NCI grants. Authors reported no conflicts.

Practical safety context

Yoga during chemotherapy should be adapted for dizziness, neuropathy, low blood counts, recent surgery, lymphedema risk, bone metastases and cardiopulmonary limits. Cultural attribution should be specific; a research program is not interchangeable with every practice labeled Tibetan yoga.

Questions for the care team

Can poses and breath practices be modified for treatment effects and mobility?
Is the teacher familiar with oncology precautions and the specific tradition studied?
Are we judging benefit by the negative primary outcomes rather than adherence-based secondary findings?

Primary sources

Last literature search: October 30, 2026 · Record appraisal: October 30, 2026

Educational evidence summary, not medical advice. Do not change cancer treatment or supportive medications without discussing the decision with the treating team.